Compare VHI & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | NBP |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 379.3M |
| IPO Year | 1994 | N/A |
| Metric | VHI | NBP |
|---|---|---|
| Price | $14.35 | $2.56 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 9.2K | ★ 919.8K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,077,000,000.00 | N/A |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.44 | $2.10 |
| 52 Week High | $20.00 | $5.19 |
| Indicator | VHI | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 44.28 |
| Support Level | $13.57 | $2.10 |
| Resistance Level | $14.44 | $3.80 |
| Average True Range (ATR) | 0.46 | 0.22 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 52.95 | 65.67 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.